Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders, has filed a supplement to its September 28, 2026, management information circular ahead of its annual general and special meeting of shareholders scheduled for November 10, 2026. The supplement corrects and restates the proposed special resolution authorizing a consolidation of the company’s Class A multiple voting shares and Class B subordinate voting shares, according to a press release issued by MissionIR.
Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. This rounding mechanism is designed to simplify the share structure post-consolidation. Additionally, the company clarified that it will implement measures to cap the aggregate voting power of multiple voting shareholders at 70% if cancellations of Class B subordinate voting shares would otherwise cause that threshold to be exceeded. This provision aims to prevent unintended concentration of voting control and protect the interests of all shareholders.
Previously submitted proxies will remain valid unless revoked or changed, and shareholders are encouraged to review the supplemental materials before the meeting. The clarification is significant for investors as it provides certainty on how the consolidation will be executed, which can affect share liquidity and voting influence. The full press release is available at https://ibn.fm/aqzMe.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The press release was distributed through MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, corporate communications solutions, and more.
For investors, the clarification of the share consolidation terms is crucial as it removes ambiguity surrounding the company’s capital structure, potentially reducing uncertainty ahead of the shareholder vote. The voting power cap at 70% ensures that multiple voting shareholders cannot exceed that threshold through cancellations, which may reassure subordinate voting shareholders about their relative influence. As Quantum BioPharma continues to advance its biopharmaceutical pipeline, including Lucid-MS for multiple sclerosis, a clear and stable governance framework is essential for maintaining investor confidence and supporting long-term growth.
